Zobrazeno 1 - 8
of 8
pro vyhledávání: ''
Autor:
Lewis R. Roberts, Nasra H. Giama, Loretta K. Allotey, Terry M. Therneau, Konstantinos N. Lazaridis, Xiaodan Zhang, Catherine D. Moser, Brian D. Juran, Mohammed M. Aboelsoud, Roongruedee Chaiteerakij, William S. Harmsen, Esha Baichoo, Teresa A. Mettler
Publikováno v:
Cancer Medicine
Genetic risk factors for cholangiocarcinoma (CCA) remain poorly understood. We assessed the effect of single-nucleotide polymorphisms (SNPs) of genes modulating inflammation or carcinogenesis on CCA risk and survival. We conducted a case-control, can
Autor:
Ninh M. La-Beck, Patricia Ohana, Esther Tahover, Hilary Shmeeda, Yasmine Amitay, Alberto Gabizon, Talia Golan, Raanan Berger, Tal Grenader
Publikováno v:
Cancer Medicine
Mitomycin C (MMC) has potent cytotoxicity but cumulative toxicity limits widespread use. In animals, pegylated liposomal mitomycin C lipid-based prodrug (PL-MLP) was well tolerated and more effective than free MMC. We evaluated PL-MLP in patients wit
Autor:
Ali Aljubran, Shouki Bazarbashi, Ahmed Mohieldin, Hussein Soudy, Ahmad Alzahrani, Mohammed Shoukri
Publikováno v:
Cancer Medicine
Phase III studies have demonstrated the efficacy of FOLFOXIRI regimens (5-fluorouracil/leucovorin, oxaliplatin, irinotecan) with/without bevacizumab in metastatic colorectal cancer (mCRC). Capecitabine is an orally administered fluoropyrimidine that
Autor:
Shuhji Seki, Hironori Tsujimoto, Kazuo Hase, Junji Yamamoto, Shuichi Hiraki, Kazumichi Yoshida, Risa Takahata, Satoshi Ono, Manabu Kinoshita, Yusuke Matsumoto, Kouji Matsumura
Publikováno v:
Cancer Medicine
CD47 is an antiphagocytic molecule that acts via ligation to signal regulatory protein alpha on phagocytes; its enhanced expression and therapeutic targeting have recently been reported for several malignancies. However, CD47 expression in gastric ca
Publikováno v:
Cancer Medicine
To examine the long-term outcomes of alternating chemoradiotherapy (ALCRT) for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) and to assess the efficacy of ALCRT for NPC. Patients with stage IIB to IVB, ECOG PS 0-2, 18-70 years-
Autor:
Sarang Abhyankar, Charles Ayas, Yeun Mi Yim, Annie Guerin, Eric Q. Wu, Carolina Reyes, Geoffrey T. Gibney, Geneviève Gauthier, Philip Galebach
Publikováno v:
Cancer Medicine
Brain metastases are a common and serious complication among patients with metastatic melanoma. The selective BRAF inhibitor vemurafenib has demonstrated clinical efficacy in patients with BRAF V600E-mutant melanoma brain metastases (MBM). We examine
Autor:
Julie A. Wolfson, Suzanne F. Jones, Howard A. Burris, Richard Pilot, Philip T. Sager, Jean Nichols, Barbara Balser
Publikováno v:
Cancer Medicine
Romidepsin is a histone deacetylase inhibitor approved by the FDA for the treatment of patients with cutaneous or peripheral T-cell lymphoma who have received prior systemic therapy. The objective of this analysis was to evaluate the potential QTc ef
Autor:
Zhimin Shao, Loris De Cecco, Maria Luisa Carcangiu, Jingyan Xue, Sylvie Ménard, Rosaria Orlandi, Rui Bi, Barbara Valeri, Silvia Veneroni, Maurizio Callari, Xiaoyan Huang, Elda Tagliabue, Marco Sandri, Matteo Dugo, Maria Grazia Daidone, Jiong Wu
Publikováno v:
Cancer Medicine
The recent dramatic increase in breast cancer incidence across China with progressive urbanization and economic development has signaled the urgent need for molecular and clinical detailing of breast cancer in the Chinese population. Our analyses of